Search Results

• The blocking model theory with consideration of the multilayer membrane structure elucidates "Planova™" virus removal filter performance

  asahi Kasei Medical Co., Ltd.
  asahi Kasei Medical Corporation is pleased to announce that research findings of the blocking model theory elucidated a more rigorous verification of the filtration behavior of "Planova™" virus removal filter.
  asahi Kasei Medical is the global market leader in virus filtration, with its "Planova™" having an unrivaled 30-year history of trusted use in the production of biotherapeutics. We aim to provide "assurance Beyond Expectation" to ensure product safety and manufacturing efficiency for therapeutics within the biopharmaceutical industry in the form of innovative yet exceptionally reliable purification consumables, equipment and support services.
  

• Relocation of asahi Kasei Bioprocess Office in Brussels

  We wish to inform you that the asahi Kasei Bioprocess Europe office in Brussels address has relocated to new premises effective 1st June 2022; our new address is:
  　　　　　　　　asahi Kasei Bioprocess Europe S.a./N.V.
  　　　　　　　　Boulevard auguste Reyers 70
  

• about asahi Kasei Bioprocess

  about asahi Kasei Bioprocess
  Our Business OverviewOur Global NetworkOur History
  Pioneering Biologics Safety and Manufacturing Efficiency
  

• asahi Kasei Medical Completes acquisition of Bionova Scientific, U.S.-based biopharmaceutical CDMO

  asahi Kasei Medical Co., Ltd.
  asahi Kasei Medical has completed its acquisition of Bionova Scientific, LLC, a provider of contract process development services and GMP-compliant contract manufacturing services to biopharmaceutical companies as announced on april 19, 2022. The acquisition closed on May 31, 2022 (US Pacific time).
  Bionova Scientific will operate as a business unit within asahi Kasei Medical's Bioprocess Division, and Darren Head, the current CEO of Bionova Scientific, will continue to lead the company. Bionova Scientific will continue to expand its business by building on its strengths as a CDMO specialized in the process design and manufacture of various types of biologics that are particularly difficult to develop. Moving forward, asahi Kasei Medical aims to provide biopharmaceutical companies with further added value and higher customer satisfaction by leveraging its existing bioprocess consumables, equipment and biosafety testing services businesses together with Bionova Scientific's biologics CDMO business.
  

• Filtration Procedure: Planova™ 15N, 20N, 35N and 75N Filters

• Integrity Test Procedure: Planova™ 15N, 20N, 35N and 75N Filters: Leakage Test Performed with the Planova Leak Tester (PLT)

• Validation Report: Planova™ 15N, 20N and 35N Filters Integrity Tests Liquid Forward-Flow Rate (LFR) Test

• Integrity Test Procedure Planova™ 15N, 20N and 35N Filters: Liquid Forward-Flow Rate (LFR) Test

• Validation Report: asahi Integrity Test Solution Kit: aGP-Ha35

• Validation Report: asahi Integrity Test Solution Kit: aGP-Ha15